🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
536.45
+2.25 (0.42%)
At close: Nov 18, 2026, 4:00 PM EST
532.00
-4.45 (-0.83%)
After-hours: Nov 18, 2026, 5:02 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

2027 catalysts span pivotal renal readouts, with AMPLITUDE interim data expected in Q1 and additional kidney and pain-study results through midyear. Povetacicept’s IgAN decision is expected Nov. 30, 2026, while non-CF revenue is projected to grow further in 2027.

Akash Tewari
Analyst, Jefferies

That is my cue. I really do appreciate it. I think this is the last fireside chat for today, but by no means am I not excited to host the Vertex management team. I am serious here. Susie, Manisha, I really do appreciate both of you making the trip over to London. I know that Reshma might come in next year. We are going to try to convince her. We will see. Either way, very, very appreciative of your time. I can tell you from a research perspective, Vertex is one of the names we are most excited about in large-cap biotech. We do think 2027 is setting up to be probably the most impactful year in terms of diversification away from cystic fibrosis, but then also a lot of strength in that franchise as well. Looking forward to the discussion.

I will hand it off to you for some intro remarks, and we will get started.

Susie Lisa
SVP of Investor Relations, Vertex

Yeah. Thanks very much, Akash and the Jefferies team, for having us. Thanks everyone in the room for sticking through to the bitter end here on Tuesday. I think it is shaping up to be a really exciting year, but we have got a lot of exciting stuff still to do in 2026. Most notably, we are eagerly awaiting our November 30 PDUFA date for povetacicept in immunoglobulin A nephropathy. I am excited for that, and I am sure we will go into more detail there. Also, by the end of the year, you will have phase II proof-of-concept data for our DM1, our myotonic dystrophy type 1 compound. As you shift into 2027, early in the year in the first quarter, you will have interim analysis phase III data from our AMPLITUDE study. This looks at inaxaplin in APOL1-mediated kidney disease patients. Really excited to see that.

We had essentially a patient population expansion study read out earlier this year in AMPLIFIED. We are excited to see the full phase III interim analysis. If that is positive, then you could see us file for accelerated approval based upon that endpoint. Also, in the first half of 2027, you will see the first results from a proof-of-concept study in povetacicept looking at myasthenia gravis. We fully enrolled that study. By the middle of the year, we would expect to see data from two phase III studies looking at suzetrigine, which is our NaV1.8 inhibitor, in diabetic peripheral neuropathy. These are the first phase IIIs for us in peripheral neuropathic pain or in chronic pain. Those are both set to complete enrollment, both of those trials, by the end of this year. They are 12-week studies, so that puts us about mid-year for data there.

There is more throughout the course of the year, but maybe I will stop there and then talk about whatever you would like. I think as we continue to pursue additional launches this year in 2026, we have talked about $500 million plus in revenue from non-CF products. You add to that with the recent acquisition of Crinetics, and PALSONIFY will get us north of that because that is just JOURNAVX and CASGEVY. We look for even more growth from non-CF products in 2027 while continuing to see a solid outlook for CF.

Akash Tewari
Analyst, Jefferies

Understood. I was at ESMO, but my team was at ASN. Otherwise, I would have been there. I do think your team made an interesting argument on efficacy for povetacicept, and I think one that maybe will age well, right? Because I think a lot of people say, "Okay, we have eGFR stabilization. They all look the same." But your team has been insistent when it comes to the consistency around geographies, hematuria, proteinuria getting under certain levels. I think you are really alluding that the puck may move. What doctors care about now versus what they may care about two, three years down the line might actually end up being different.

Talk to me about your confidence that povetacicept is differentiated from an efficacy perspective beyond just proteinuria, and what are you hearing on the ground in terms of the evolving landscape and endpoints that doctors are going to increasingly focus on?

Susie Lisa
SVP of Investor Relations, Vertex

Sure. Yeah. Thanks for the very good question. We do think that we have potential best-in-class efficacy with povetacicept. I will go into detail. We know we believe we have best-in-class patient administration or convenience factors, and hopefully we can talk about that too. But with respect to efficacy, recall that at our interim analysis, we had a 52% reduction in proteinuria, and that was just at 36 weeks. Competitors who saw a similar rate of reduction was actually out to 40 weeks. We know proteinuria continues to decline, so that was an earlier snap of it. We had greater than 80% reduction in resolution of hematuria, and we also had 42% of patients getting to KDIGO guidelines. I think how physicians are thinking about this, first off, povetacicept patients are otherwise healthy, typically younger. Average age of diagnosis is in their mid-40s.

No patient, no physician wants blood or protein in their urine. I think even small differences in proteinuria reduction compounded over time for a lifelong therapy could result in differences that are meaningful in terms of kidney function. Not necessarily do we think that stable is stable, but acting sooner, faster, having faster rates of decline could result in overall better clinical outcomes in terms of potentially staving off progression to dialysis, transplant, or even death. That will be a long time to prove, but we are excited with the profile of povetacicept being able to take that forward. As I mentioned, on the patient administration aspect, we think a clear advantage there given that we are once every four weeks dosing with an auto-injector with very low dose, 0.46 mL. We also have lower viscosity than peers, so it is less painful.

As I mentioned, at home with an auto-injector versus peers who are every four weeks are today with a prefilled syringe at much higher dosages, or other peers are at weekly dosing.

Akash Tewari
Analyst, Jefferies

Mm. Now, one of the things I have noticed, every other company I really talk to, when it comes to IgAN and eGFR, one-year interim, one-year interim, you actually, you really do stand out. There is not a single other company I talk to who actually talks about the importance of two-year data, A, for global regulators, but B, as you think about building a dataset where maybe it takes a little more time for the hematuria or the proteinuria, for povetacicept to differentiate on efficacy, right? Talk to me about data that you are going to generate long-term that would maybe support your view that any levels of proteinuria may actually lead to a worse outcome for patients, and how can you maybe generate that data internally at Vertex?

Talk to us about why you are such an outlier about looking for that two-year interim, I mean, that two-year endpoint, and what do you think that gives you from an advantage perspective about the global market opportunity for these drugs?

Susie Lisa
SVP of Investor Relations, Vertex

Yeah, that's really a key part of it, there's only a pathway today currently for accelerated approval in the U.S. I should also mention we have filed for accelerated approval in Kingdom of Saudi Arabia, where there's a pathway there. Otherwise, in Europe and in the Asian markets, it is a firm two-year eGFR endpoint. While it's a significantly large rare market opportunity in the U.S., we estimate 160,000 patients are today biopsy-confirmed, diagnosed with IgAN, and we'd estimate a similar size population in Europe, that 330 sort of type of number pales in comparison to what we'd estimate as 1.5 million or 1.6 million globally. We view Asia as the much larger patient opportunity. Just today, we saw the Chinese government approve two B-cell inhibitor agents for reimbursement in China, and I think that speaks to the need there.

We have partnered commercially with Ono Pharma in Japan and surrounding countries and with Zai Lab in China and surrounding countries, excuse me. I do think that that longer endpoint will begin to, we believe, bear out some of our thesis about less proteinuria sooner is always a better thing. Less hematuria, better hematuria resolution sooner is a better thing, because it shouldn't be there in your urine, and let's try and preserve as much nephron function as we can.

Akash Tewari
Analyst, Jefferies

I just thought of this question now because you mentioned Zai and Ono you're partnered with, and there is this dynamic of the MFN of it all, right? I hosted Pfizer earlier today. There was a panel, I think, yesterday which really said, "This is not a red wave, blue wave dynamic. This kind of a more equitable share of healthcare expenditure is a growing issue, and it's not going to go away regardless of whether there's a Democrat or Republican in office in the United States." You have very uniquely partnered. You're working with external partners when you're thinking about the ex-U.S. opportunity.

Can you talk a bit about how that gives you maybe more flexibility about preserving pricing in the United States, but then also really being able to meet some of these other countries where, from an economic perspective, they need to make sure it works for them? How does a partner actually help you do both?

Susie Lisa
SVP of Investor Relations, Vertex

Right. I think that certainly we chose to partner with Zai and Ono Pharma more for the capabilities that they bring and a recognition that that was the most expedient and cost-effective way for us to do that. If there is more pricing flexibility in that type of construct, that would be a nice byproduct. But we absolutely are thinking about povetacicept as one of the first launches in this more MFN-aware environment, if you will. Recall for us, JOURNAVX is U.S. only. CASGEVY is an in-hospital procedure and actually has very consistent pricing globally, sometimes even priced a bit higher outside the U.S. In cystic fibrosis, we don't go into the details. Many are under confidential agreement.

But when you have your fifth medicine and continue to advance the therapy and launch new therapies, I think that puts you in a slightly better position than someone who launched 10, 15, 20 years ago and has just taken price increases in the U.S. So, we are absolutely thinking about Pove with that construct, and I think that's probably another one of the advantages that we can bring to this market, is our experience in cystic fibrosis in terms of negotiating reimbursement agreements in single-payer systems and educating as to the value that our transformative therapies can bring. We're absolutely thinking about that as we consider the market opportunities in the countries where we'll enter. Again, I think it gets back to younger patients, otherwise healthy, dialysis or transplant are pretty tough alternatives, and working through that.

Akash Tewari
Analyst, Jefferies

Okay, understood. Now, I know there's kind of too many debates going into the Pove PDUFA. One is on monitoring requirements, and the other one is really just from a manufacturing perspective. Going into any event, I think companies will naturally qualify and tell you why things are okay. I've noticed your team and Reshma very much has called their shot. You have a definitive view of what really the label will look like, the overall profile of povetacicept. Then I think again, as much as you've been pushed and as annoying it can be, you guys have expressed continued confidence on manufacturing. Can you expand a bit on why your team is so confident that you'd be able to deliver on both of those fronts going into the PDUFA?

Susie Lisa
SVP of Investor Relations, Vertex

Sure. I think I'll try and address both the manufacturing talk or rumors, as well as why we think we'll have a label that's consistent with the class, i.e., no monitoring of IgG. Frankly, it's data-driven. When you have a priority review, there is a strict six-month schedule. There's a cadence of events, inspections, et cetera. What we have said consistently is that all of that has happened on the cadence that you would expect, and that things remain on track. Therefore, we have high visibility and confidence in our November 30th PDUFA date. Similarly, with respect to why we think we'll have a label that will be consistent with the class is, the only reason you would have monitoring for IgG is if you had reasons to believe there is increased infection risk with your therapy.

Here, quite definitively, we have not seen that in the interim analysis. You had a very low rate of serious infections of 0.5%, and it was exactly the same in both the placebo and in the drug arm. We just don't see the evidence for it. There's also, I think, pretty wide disparities in how the various trials have been constructed in terms of frequency of monitoring, even thresholds or definitions. With lack of infection risk demonstrated in the data, and based on our ongoing view of things, that's why we believe we'll have a label consistent with the class, and again, are on track for November 30th.

Akash Tewari
Analyst, Jefferies

Understood. Now, I think sometimes when I talk to investors, it's funny. You can say three good things, and then it'll be like, "Well, what did they not talk about?" It's interesting sometimes with povetacicept, you stress the global opportunity, but then the natural question becomes, "Oh, is the team less confident about the uptake in the U.S. market?" We've seen with both therapies that have currently launched, really healthy and consistent patient adds, and we've seen the class kind of expand. But there is this kind of debate of, well, what is the low-hanging fruit? As you go through kind of the severe proteinuria patients, what's the moderate uptake look like, and then really, what's long-term safety that patients want? To be fair, we've also heard this sometimes with KOLs.

To be more focused, you're going to be launching without necessarily the eGFR long-term data, but you are going to be having the proteinuria reduction. Is your team confident that you can deliver the same uptake that you've seen with some of the existing therapies in the class? Really, what's your view of how the U.S. market opportunity plays out over time?

Susie Lisa
SVP of Investor Relations, Vertex

Yeah. I think that we have been quite happy to see the initial uptake from the two competitors who've already launched, and speaks to, again, that unmet need. These are otherwise patients who feel like they're kind of ticking time bombs, waiting to see how fast their kidney decline progresses. I think it's been great to see, and points to what probably should be more of a TAM discussion, frankly, than a share discussion, I would say.

But I do think that we view our being third to market as not, and not having eGFR data, we don't view those as hindrances per se. I think probably the most heavily proteinuria patients who'd been diagnosed a while ago with the first entrant, surely you'll see them pick that up. But even if you look at a better-than-expected launch, maybe 5,000 patients on drug already, that still leaves 155,000 in the U.S. for us to go after. And I think over time, too, the opportunity for a switching market as well, although initial focus is naive. I do think you had mentioned it briefly, but I'd emphasize again the consistency of our results across all subgroups, and namely the proteinuria decline is entirely consistent overall with the North American subgroup, and that's not the case with the two competitors.

In a U.S. launch, that'll be a key feature of our detailing messaging overall. We also can talk about pipeline and a product, where Pove is already in phase III for primary membranous nephropathy, and the rest of our pipeline, we mentioned inaxaplin and AMKD. We're also looking at autosomal dominant polycystic kidney disease.

And we aim to have the largest share of voice. We haven't given the exact number, but we'll have the largest field force in the disease-modifying agents. Then finally, it may be a smaller point, but 80% of our CF patients use our patient services programs. So, this is where you can call, get a live person, help with getting on drug, navigating reimbursement, et cetera, and we'll replicate that model in renal.

Akash Tewari
Analyst, Jefferies

Understood. And you brought a point that actually has come up with doctors. There is a bit of uncertainty on what is IgAN, and sometimes you look and you say, "Actually, it's membranous nephropathy." How much of a competitive advantage would it be that you have an APRIL/BAFF where, yes, you have IgAN on the label, but B, you also have approvals in other kidney indications in terms of kind of capturing patients before a nephrologist figures out what they ultimately have, right? Do you feel like that's a key differentiator when you think about your clinical data package versus your peers?

Susie Lisa
SVP of Investor Relations, Vertex

I guess maybe I would frame it as we think overall, having that mindshare of physicians knowing, nephrologists knowing that we have four disease-modifying therapies, this renal renaissance where they previously have really just had repurposed cardiovascular medicines. If you recall, our IgAN study was the fastest to enroll, and I think that was because we didn't just show up and say, "Here, we have Pove." They knew us from our AMKD enrollment. They know us from our other activities as well. I'd say it's probably a combination of the two, but definitely seeking to have significant mindshare with physicians and translate that into faster enrollments, faster uptake of commercialized products, et cetera.

Akash Tewari
Analyst, Jefferies

Now, maybe switching to inaxaplin, and who knows, maybe early next year, we could have an interim. I mean, I don't think people understand how quick AMPLITUDE could be reading out. There's another example of where I feel like your team and Reshma has been very, let's say, dogged with her language and not qualified going into an event. Again, you would have every excuse to say, "Look at PARASOL, look at the underserved population. We have precedents in FSGS where you can use proteinuria as a basis for an approval." But I haven't heard you say that. I haven't heard your team say that, and your consistent messaging is FDA is looking at eGFR, and that's what we're looking at as well. Why the confidence on being able to hit on eGFR at this interim? I know it's over 200 patients.

Can you comment a bit about what you've seen in terms of long-term duration with your phase II datasets as you follow these patients over an extended period of time?

Susie Lisa
SVP of Investor Relations, Vertex

Yeah. So on the first question, so what we know about APOL1-mediated kidney disease is you need two APOL1 variants, right? If you have those variants, your disease progression, your decline in kidney function is likely to be about 50% faster than those who don't have the variants. So you're losing six to seven mLs per minute per year versus more like, say, four in people who don't have the two APOL1 variants. We also know that our drug, inaxaplin, is inhibiting about 98% plus of APOL1. Then finally, I think I'd point you to the two phase II datasets that we have, where in our initial phase II study, we saw at 13 weeks a 47.6% reduction in proteinuria.

I think consistently, the datasets continue to come in that that is correlated with what we need to achieve here would be, it's a separation of the curves of eGFR slope, inaxaplin versus placebo on top of standard of care. Given how rapidly these patients decline, how well we know we're inhibiting APOL1, and what we've seen in terms of proteinuria reduction, and even with IgAN, seeing how that does translate to relative stabilization, that's why we are optimistic for the interim analysis. Definitively, our conversations with FDA have been, we're measuring both eGFR slope as well as proteinuria, but we need to hit on eGFR slope to file for the accelerated approval. We also recently saw on the AMPLIFIED results in the more modest proteinuria group, so that was 0.3 to 0.7 grams per gram versus AMPLITUDE, the phase III study is 0.7 or above.

Even there, we saw at 13 weeks, a 44% reduction in proteinuria. Very consistent, even with less dynamic range in terms of the reduction of proteinuria. That is all what gives us confidence, but we need to see the data, and as you said, we will see it early in 2027.

Akash Tewari
Analyst, Jefferies

Understood. On the Q3 call, I think Reshma made some very interesting and quite specific comments about how she expected eGFR in the placebo arm to really perform, and your team actually has presented natural history data on this as well. I think one of the things that maybe most investors know, diabetic might be a little trickier than FSGS, but what I don't think people appreciate is that there's also a lot of variation in terms of rates of decline, even within specific genotypes in APOL1 itself. Here's where it gets kind of interesting. The confidence in which Reshma said what she expected is also backed by, I think, some of your natural history publications, but then there's this interesting dynamic of you have unique visibility on, even if they're not diabetic, what variance of APOL1 is in AMPLITUDE. Some have even a 17-point decline.

I mean, there's some really, really rapid progressors there. Let's put it this way. What did you learn from your natural history publications in terms of the right types of patients to enroll if you're focused on hitting on eGFR? Can you give us a hint of what's been the breakdown in AMPLITUDE for the 200 patients that are in that interim analyses?

Susie Lisa
SVP of Investor Relations, Vertex

No, I cannot on the second part of your question. I will say that there has been a huge initiative on our part to work with partners and to get genotyping studies up and running and underway, and then to enroll patients in the study. This was a very global study as well. It's taken us a very long time to enroll, and are quite pleased that we've been able to conclude that. I think to us, and the AMPLIFIED results validated this as well, there had been a school of thought that it really was FSGS that mattered.

Akash Tewari
Analyst, Jefferies

Right.

Susie Lisa
SVP of Investor Relations, Vertex

We definitively view that as not what matters. That's just a histological diagnosis of a scarring pattern. What matters is two APOL1 variants. I think that our view is that it is actually, while there may be variations, that is the crux of the matter, and we'll take all comers. In fact, we would also take, if you have FSGS, if you've had the biopsy diagnosis, you're welcome in the study. If you haven't, you're welcome in the study. It really just comes down to when we genotype you, do you have those two variants? So perhaps more to come on ranges within that. Again, our natural history or the literature would suggest that placebo arms should decline something in that six, seven mLs per minute per year.

Akash Tewari
Analyst, Jefferies

Understood. As we think about the market opportunity here, I think people have grown. We get IgAN, right? This is disease modifying, no one wants to get on dialysis. On AMKD, I think, I don't know if people understand what the long-term TAM could be, but there's also unique challenges. You're talking about an underserved community, mostly African American population, and it's going to take time to really educate and then actually get patients on therapy. So, when your team thinks about the TAM longer term, how does that compare to, let's say, the IgAN opportunity for povetacicept? Then number two, what will it take to really commercialize a drug in this market, and how should we think about uptake over time?

Susie Lisa
SVP of Investor Relations, Vertex

Yeah. So, I think unlike IgAN, where these patients are already biopsy-confirmed, diagnosed, and waiting, oftentimes with an AMKD patient, they've not been genotyped. They just know that they have chronic kidney disease, and they probably know that they're heavily proteinuric and losing function rapidly. I think increasingly physicians are aware that they should be genotyping both their Black and actually Hispanic patients, to see if they have the two APOL1 variants. We have been doing a lot of education work. Again, I mentioned the genotyping studies. We also partnered with Alonzo Mourning, who had the disease, an NBA Hall of Famer. He's been tireless in his efforts in reaching out to community groups and church groups, et cetera. I think the intent here is likely to launch with a companion diagnostic and build this as the first precision genetic-

medicine for kidney disease. As our physician mentioned at our ASN event, the prevalence among Black families is well in excess of their percentage of the population. There is not a Black family you can meet that does not know someone in their family with kidney disease. I think increasing awareness, and once you have a disease-modifying therapy-

I think it is a little bit of our hope is build it, you will come. We do think, and we do not give market size, but the epidemiology estimate we have is similar in size to Pove, and that is the 150,000 that we give in the U.S., for those with proteinuria, modest to severe proteinuria, two APOL1 alleles, and no comorbidities. If you add comorbidities like type 2 diabetes to it, you get another 100,000 patient opportunity.

Akash Tewari
Analyst, Jefferies

Understood. Last question, because I do not think there is another one, so we can go a little over. Crinetics. This was a deal where I do not know if everyone expected it, because again, you had a bunch of kidney readouts, so it was not like you were a company that was lacking in terms of impactful catalysts for 2027. It did feel like Reshma really wanted to be, A, on the offensive, but B, it was, "I know more than you. I have been able to diligence this asset." I do think that is something I would love for you to talk a bit more about, right? I think for the CAH drug, really strong A4 reductions. The investor debate was always around liver toxicity. What have you learned when you did the initial diligence on the deal?

What have you learned as you have gotten more longer-term follow-up data, and also maybe more patients, that would help investors feel comfortable about the safety profile for that drug for CAH?

Manisha Pai
Executive Director of Investor Relations, Vertex

Sure. I will start with your question just around the transaction and why we did it and when we did it. We had been looking at Crinetics since earlier this year, since January or so. We really liked what we saw. It fit perfectly with our strategy of severe disease with well-known, well-understood causal biology, specialty markets. So, a perfect fit. As we continued our diligence, we began to think this company might be undervalued, and we wanted to move quickly and snap it up before others sort of cottoned onto that. In terms of safety in the CAH study, there was only one liver event in the phase II that could not be ruled out definitively as related to atumelnant. But there were no cases of Hy's law, and it was found toward the very end of the study.

Akash Tewari
Analyst, Jefferies

Right.

Manisha Pai
Executive Director of Investor Relations, Vertex

The patient went off drug, and it resolved. I will add that phase II is ongoing in an open-label extension, and we have not seen any additional liver events in those data, and we will present the fuller data set at a medical meeting that is in 2027.

Akash Tewari
Analyst, Jefferies

Understood. Maybe just lastly, just any comments about enrollment for the ongoing phase III and timing there?

Manisha Pai
Executive Director of Investor Relations, Vertex

Yeah. We expect to complete enrollment in Q1 of 2027, and then it is 32 weeks of dosing, so we could be looking at late 2027 or early 2028 for a data readout.

Akash Tewari
Analyst, Jefferies

I cannot help but think, if we think about the, quote-unquote, "liver event" that happened in phase II was around 12 weeks, by the time we get into mid next year, if there was I mean, it does seem like as more time goes on, the street as a whole should feel a little more comfortable about the safety profile. Would you agree with that?

Manisha Pai
Executive Director of Investor Relations, Vertex

Yeah. I think as with any ongoing study, with an IDMC monitoring it, et cetera, if there is something that is a deal-breaker or alarming, that we would find out about it. Again, we look forward to sharing the phase II open-label extension data.

Akash Tewari
Analyst, Jefferies

Amazing. Thank you so much. I really do appreciate it. Wonderful discussion.

Susie Lisa
SVP of Investor Relations, Vertex

Thank you.

Manisha Pai
Executive Director of Investor Relations, Vertex

Thank you.

Susie Lisa
SVP of Investor Relations, Vertex

Take care.